Applied Therapeutics Shares Rise 11% After Pre-NDA Meeting With FDA
06 Settembre 2023 - 5:08PM
Dow Jones News
By Chris Wack
Applied Therapeutics shares were up 11% to $1.40 after the
company successfully completed a recent pre-New Drug Application
meeting with the U.S. Food and Drug Administration regarding its
govorestat Galactosemia program.
The stock hit its 52-week high of $2.18 on May 1, and is down 1%
in the past 12 months.
Based on discussions with the FDA, the biopharmaceutical company
believes it is aligned with the FDA and plans to submit an NDA for
govorestat for the treatment of Galactosemia in the fourth
quarter.
Applied Therapeutics said the FDA expressed its support for a
potential NDA based on the govorestat data generated to date in
Galactosemia, and provided constructive recommendations for
successful NDA acceptance and review.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
September 06, 2023 10:53 ET (14:53 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Grafico Azioni Applied Therapeutics (NASDAQ:APLT)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Applied Therapeutics (NASDAQ:APLT)
Storico
Da Giu 2023 a Giu 2024
